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Abstract
The retinoblastoma (Rb) tumor suppressor gene product, pRb, has an established role in the
implementation of cellular senescence, the state of irreversible G1 cell cycle arrest provoked by
diverse oncogenic stresses. In murine cells, senescence cell cycle arrest can be reversed by
subsequent inactivation of pRb, indicating that pRb is required not only for the onset of cellular
senescence, but also for the maintenance of senescence program in murine cells. However, in
human cells, once pRb is fully activated by p16INK4a, senescence cell cycle arrest becomes
irreversible and is no longer revoked by subsequent inactivation of pRb, suggesting that p16INK4a/
Rb-pathway activates an alternative mechanism to irreversibly block the cell cycle in human
senescent cells. Here, we discuss the molecular mechanism underlying the irreversibility of
senescence cell cycle arrest and its potential towards tumor suppression.
Background
Cellular senescence is the state of stable cell cycle arrest
provoked by a variety of potentially oncogenic stimuli,
such as telomere shortening, DNA damage or activation
of certain oncogenes [1-3]. Cellular senescence appears to
be acting as a barrier to cancer, preventing damaged cells
from undergoing aberrant proliferation [4-10]. Two well
established tumor suppressor proteins, pRb and p53, have
been shown to play key roles in cellular senescence [1-3].
The activities of pRb and p53 are dramatically increased
during cellular senescence and inactivation of these pro-
teins in senescent mouse embryonic fibroblasts (MEFs)
results in the reversal of the senescence phenotype leading
to cell cycle re-entry, suggesting that pRb and p53 are
required not only for the initiation of senescence program
but also for the maintenance of the senescence state in
murine cells [1-3,11,12]. In human senescent cells, how-
ever, once pRb is fully engaged, particularly by its activator
p16INK4a, senescence cell cycle arrest become irreversible
and is no longer revoked by subsequent inactivation of
pRb and p53 [13-15]. Interestingly, subsequent inactiva-
tion of pRb and p53 enables human senescent cells to
reinitiate DNA synthesis but fails to drive the complete
cell cycle, suggesting that these cells may be arrested in G2
or M phase of the cell cycle [13,14]. This pRb- and p53-
independent cell cycle block, which seems to be specific
for human cells, is likely to act as a second barrier to cel-
lular immortalization and may help to explain the
remarkable stability of the senescence cell cycle arrest in
human cells [2,15]. Recent work in our lab has uncovered
an unexpected role for the p16INK4a/Rb-pathway and pro-
vided a new insight into how senescent cell cycle arrest is
enforced in human cells [16]. In this commentary, we will
take a closer look at the genes and mechanism involved.
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The G1/S control in cellular senescence
In higher eukaryotes, pRb is a crucial gatekeeper of cell
cycle progression [17-21]. The activity of pRb is tightly
regulated by various post-translational modifications,
such as phosphorylation, acetylation and ubiquitination,
and is thought to impose a block on G1 progression that
is alleviated by phosphorylation [17-21]. In particular, a
series of cyclin-dependent kinases (CDKs), CDK2, CDK4
and CDK6, play a critical role in the phosphorylation of
pRb [18,22-25]. When pRb is phosphorylated by these
CDKs, pRb loses its ability to bind E2F/DP transcription
factor complexes resulting in entry into S-phase of the cell
cycle [26-28]. However in senescent cells, the activity of
CDKs is blocked by elevated expression of CDK inhibi-
tors, p21Cip1/Waf1/Sdi1 and p16INK4a [29-32]
p21Cip1/Waf1/Sdi1 is a founding member of the mammalian
CDK inhibitor family and is one of the best characterized
transcriptional targets of the p53 tumor suppressor pro-
tein [29,33-36]. Thus, p21Waf1/Cip1 links the p53- pathway
to the Rb- pathway, providing a tight security network
towards tumor suppression. Indeed, the role of p21Cip1/
Waf1/Sdi1 expression is well documented in various cell cul-
ture studies; up-regulation of p21Cip1/Waf1/Sdi1 expression
participates in processes such as DNA damage-induced
cell cycle arrest, cellular senescence and terminal differen-
tiation that may prevent tumor formation [22]. However,
since mutations in the p21Waf1/Cip1/Sdi1  gene are rarely
observed in human cancers and mice lacking p21Waf1/Cip1/
Sdi1 gene do not exhibit any predisposition to spontaneous
tumor formation [37-40], it remains unclear whether
p21Cip1/Waf1/Sdi1 indeed plays a key role in tumor suppres-
sion in vivo.
The INK4a gene encodes another type of CDK inhibitor,
p16INK4a, which specifically binds to and inactivates D-
type CDKs, CDK4 and CDK6 [41]. The binding of
p16INK4a to CDK4/6 also induces redistribution of Cip/Kip
family CDK inhibitors, p21Cip1/Waf1/Sdi1 and p27Kip1, from
cyclinD-CDK4/6 to cyclinE-CDK2 complexes resulting in
the inactivation of CDK2-kinase [22,42,43]. Thus, induc-
tion of p16INK4a collaborates with p21Cip1/Waf1/Sdi1 to pre-
vent phosphorylation of pRb, leading to a stable G1 arrest
in senescent cells [32]. Importantly, the p16INK4a gene is
frequently inactivated in a wide range of human cancers
and is therefore recognized as a tumor suppressor gene
[32]. This may also be because the coding region of the
p16INK4a gene is partly shared with another tumor sup-
pressor gene called p14ARF  (also called as p19ARF  in
mouse) [32,44,45]. In human cancer, however, a large
number of the point mutations within this region only
affect p16INK4a activity but not p14ARF activity, indicating
that p16INK4a /Rb-pathway, in itself, also play key roles in
tumor suppression [32].
Cytokinetic block: a second barrier in cellular 
senescence
Although p16INK4a is known to exert its effects through
pRb, subsequent inactivation of pRb stimulates DNA syn-
thesis but not cell proliferation if p16INK4a is ectopically
expressed prior to inactivation of pRb in human cells [14].
By contrast, inactivation of pRb is sufficient to override
the p16INK4a effect if pRb is inactivated prior to p16INK4a
expression [14]. It is therefore likely that once pRb is fully
activated by p16INK4a, pRb activates yet another mecha-
nism that irreversibly causes cell cycle arrest either in G2
or M phase [2,13,14]. Indeed, a dramatic increase of poly-
nucleated cells is observed when pRb and p53 were subse-
quently inactivated in human cells expressing high level
of p16INK4a [16], suggesting that this mechanism may tar-
get cytokinesis.
To delineate the molecular events underlying this cytoki-
netic block in human senescent cells, we took advantages
of using SVts8 cells, a conditionally immortalized human
fibroblasts cell lines that express a temperature-sensitive
(ts) mutant of simian virus 40 large T antigen (LT) and ele-
vated level of endogenous telomerase [46,47]. Using
SVts8 cells, we were able to examine the irreversibility of
senescence cell cycle arrest under various different condi-
tions and have shown that p16INK4a/Rb-pathway cooper-
ate with mitogenic signals to enforce irreversible
cytokinetic block through activating production of reac-
tive oxygen species (ROS) [16].
Although ROS are required for the physiological function
of the cells, excessive ROS cause anti-proliferative effects
such as apoptosis and/or cellular senescence [48]. During
low stress condition, mitogenic signals inactivate pRb and
therefore activate E2F/DP complexes to stimulate S-phase
entry [22,26-28]. Moreover, E2F/DP activation decrease
ROS levels by regulating genes involved in ROS produc-
tion [16]. Thus, although mitogenic signals have the
potential to stimulate ROS production, this effect appears
to be counterbalanced by E2F/DP activity in proliferating
normal human cells [16]. In condition of high cellular
stress, however, the activity of E2F/DP is blocked by
p16INK4a/Rb-pathway. In this setting, mitogenic signaling,
in turn, increases the ROS production, thereby activating
PKCδ, a critical downstream mediator of the ROS signal-
ing pathway [16,49,50]. Importantly moreover, once,
activated by ROS, PKCδ, promotes further generation of
ROS, thus establishing a positive feed back loop to sustain
ROS- PKCδ signaling [16]. Sustained activation of ROS-
PKCδ signaling irreversibly blocks cytokinesis, at least
partly through reducing the level of WARTS (also known
as LATS1), a mitotic exit network (MEN) kinase required
for cytokinesis [51-53], in human senescent cells [16].
Thus, elevated levels of p16INK4a establish an autonomous
activation of ROS- PKCδ signaling, leading to an irrevoca-Cell Division 2007, 2:10 http://www.celldiv.com/content/2/1/10
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ble block to cytokinesis in human senescent cells (see
model in Figure 1). This system may serve as a fail-safe
mechanism, especially in case of the accidental inactiva-
tion of pRb and p53 in human senescent cells [15,16]. It
is noteworthy that we were unable to see activation of
PKCδ during replicative senescence in MEFs [16]. This dif-
ference may account for the reversibility of murine cell
senescence.
Concluding remarks
Although we can not rule out the possibility that other
mechanisms might also involved in the irreversible senes-
cence cell cycle arrest [54-59], our results reveal a novel
activity of the p16INK4a/Rb- pathway and facilitate our
understanding of how cellular senescence is securely con-
trolled in human primary cells. Understanding the strict
irreversibility of cellular senescence will provide valuable
new insights into the development of cancer and open up
new possibilities of its control [60-62].
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The roles of p16INK4a/RB-pathway in senescence cell cycle arrest Figure 1
The roles of p16INK4a/RB-pathway in senescence cell cycle arrest. In proliferating cells, the effects of mitogenic signals 
in ROS production are counterbalanced by E2F/DP activity. However, when E2F/DP activity is shut down by fully activated 
pRb, mitogenic signaling, in turn, increases the level of ROS and elicits a positive feedback activation of ROS/PKC-δ signaling 
pathway. Elevated levels of p16INK4a therefore establish an autonomous activation of ROS/PKC-δ signaling, leading to an irrevo-
cable block to cytokinesis in human senescent cells.
S
&\FOLQ'
&'.
()'3
S5%
,1.D
3.&Ǭ '1$UHSOLFDWLRQ
&\WRNLQHVLV
0LWRJHQLF
6LJQDOV
526
'1$UHSOLFDWLRQ
& &\ \ \W W WR R RN N NL L LQ Q QH H HV V VL L LV V V
2QFRJHQLF
6WUHVVCell Division 2007, 2:10 http://www.celldiv.com/content/2/1/10
Page 4 of 5
(page number not for citation purposes)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Acknowledgements
We thank Dr. D. Mann for helpful comments on the manuscript. We also 
thank members of the Hara lab for helpful discussion during the preparation 
of this manuscript. This work was supported by grants from Ministry of 
Education, Science, Sports and Technology of Japan, Ministry of Health, 
Labor and Welfare of Japan, and Sankyo Foundation of Life Science to E. H. 
A. T. is supported by the Japan Society for the Promotion of Science.
References
1. Ben-Porath I, Weinberg RA: When cells get stressed: an integra-
tive view of cellular senescence.  J Clin Invest 2004, 113(1):8-13.
2. Campisi J: Senescent cells, tumor suppression, and organismal
aging: good citizens, bad neighbors.  Cell 2005, 120(4):513-522.
3. Herbig U, Sedivy JM: Regulation of growth arrest in senescence:
telomere damage is not the end of the story.  Mech Ageing Dev
2006, 127(1):16-24.
4. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M,
Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M:
Tumour biology: senescence in premalignant tumours.
Nature 2005, 436(7051):642.
5. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegel-
berger B, Stein H, Dorken B, Jenuwein T, Schmitt CA: Oncogene-
induced senescence as an initial barrier in lymphoma devel-
opment.  Nature 2005, 436(7051):660-665.
6. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T,
van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS:
BRAFE600-associated senescence-like cell cycle arrest of
human naevi.  Nature 2005, 436(7051):720-724.
7. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher
JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP:
Crucial role of p53-dependent cellular senescence in sup-
pression of Pten-deficient tumorigenesis.  Nature 2005,
436(7051):725-730.
8. Sharpless NE, DePinho RA: Cancer: crime and punishment.
Nature 2005, 436(7051):636-637.
9. Campisi J: Suppressing cancer: the importance of being senes-
cent.  Science 2005, 309(5736):886-887.
10. Narita M, Lowe SW: Senescence comes of age.  Nat Med 2005,
11(9):920-922.
11. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T: Acute
mutation of retinoblastoma gene function is sufficient for
cell cycle re-entry.  Nature 2003, 424(6945):223-228.
12. Dirac AM, Bernards R: Reversal of senescence in mouse fibrob-
lasts through lentiviral suppression of p53.  J Biol Chem 2003,
278(14):11731-11734.
13. Dai CY, Enders GH: p16 INK4a can initiate an autonomous
senescence program.  Oncogene 2000, 19(13):1613-1622.
14. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P,
Campisi J: Reversal of human cellular senescence: roles of the
p53 and p16 pathways.  EMBO J 2003, 22(16):4212-4222.
15. Ramsey MR, Sharpless NE: ROS as a tumour suppressor?  Nat Cell
Biol 2006, 8(11):1213-1215.
16. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K,
Nakayama KI, Ide T, Saya H, Hara E: Mitogenic signalling and the
p16INK4a-Rb pathway cooperate to enforce irreversible cel-
lular senescence.  Nat Cell Biol 2006, 8(11):1291-1297.
17. Sherr CJ, McCormick F: The RB and p53 pathways in cancer.
Cancer Cell 2002, 2(2):103-112.
18. Cobrinik D: Pocket proteins and cell cycle control.  Oncogene
2005, 24(17):2796-2809.
19. Uchida C, Miwa S, Kitagawa K, Hattori T, Isobe T, Otani S, Oda T,
Sugimura H, Kamijo T, Ookawa K, Yasuda H, Kitagawa M: Enhanced
Mdm2 activity inhibits pRB function via ubiquitin-dependent
degradation.  EMBO J 2005, 24(1):160-169.
20. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue
NB: Acetylation control of the retinoblastoma tumour-sup-
pressor protein.  Nat Cell Biol 2001, 3(7):667-674.
21. Gonzalo S, Garcia-Cao M, Fraga MF, Schotta G, Peters AH, Cotter SE,
Eguia R, Dean DC, Esteller M, Jenuwein T, Blasco MA: Role of the
RB1 family in stabilizing histone methylation at constitutive
heterochromatin.  Nat Cell Biol 2005, 7(4):420-428.
22. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative
regulators of G1-phase progression.  Genes Dev 1999,
13(12):1501-1512.
23. Ciemerych MA, Sicinski P: Cell cycle in mouse development.
Oncogene 2005, 24(17):2877-2898.
24. Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, Kiyokawa H,
Kaldis P: Combined loss of Cdk2 and Cdk4 results in embry-
onic lethality and Rb hypophosphorylation.  Dev Cell 2006,
10(5):563-573.
25. Malumbres M, Barbacid M: Cell cycle kinases in cancer.  Curr Opin
Genet Dev 2007, 17(1):60-65.
26. Dimova DK, Dyson NJ: The E2F transcriptional network: old
acquaintances with new faces.  Oncogene 2005,
24(17):2810-2826.
27. Trimarchi JM, Lees JA: Sibling rivalry in the E2F family.  Nat Rev
Mol Cell Biol 2002, 3(1):11-20.
28. Rowland BD, Bernards R: Re-evaluating cell-cycle regulation by
E2Fs.  Cell 2006, 127(5):871-874.
29. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning
of senescent cell-derived inhibitors of DNA synthesis using
an expression screen.  Exp Cell Res 1994, 211(1):90-98.
30. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G: Regulation
of p16CDKN2 expression and its implications for cell
immortalization and senescence.  Mol Cell Biol 1996,
16(3):859-867.
31. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic
ras provokes premature cell senescence associated with
accumulation of p53 and p16INK4a.  Cell 1997, 88(5):593-602.
32. Gil J, Peters G: Regulation of the INK4b-ARF-INK4a tumour
suppressor locus: all for one or one for all.  Nat Rev Mol Cell Biol
2006, 7(9):667-677.
33. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM,
Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential
mediator of p53 tumor suppression.  Cell 1993, 75(4):817-825.
34. Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in
vivo by an associated 20K regulatory subunit.  Nature 1993,
366(6456):707-710.
35. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21
Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyc-
lin-dependent kinases.  Cell 1993, 75(4):805-816.
36. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21
is a universal inhibitor of cyclin kinases.  Nature 1993,
366(6456):701-704.
37. El-Deiry WS: p21/p53, cellular growth control and genomic
integrity.  Curr Top Microbiol Immunol 1998, 227:121-137.
38. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking
p21CIP1/WAF1 undergo normal development, but are
defective in G1 checkpoint control.  Cell 1995, 82(4):675-684.
39. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon
GJ: Radiation-induced cell cycle arrest compromised by p21
deficiency.  Nature 1995, 377(6549):552-557.
40. Pantoja C, Serrano M: Murine fibroblasts lacking p21 undergo
senescence and are resistant to transformation by oncogenic
Ras.  Oncogene 1999, 18(35):4974-4982.
41. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-
cycle control causing specific inhibition of cyclin D/CDK4.
Nature 1993, 366(6456):704-707.
42. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G: Induced
expression of p16(INK4a) inhibits both CDK4- and CDK2-
associated kinase activity by reassortment of cyclin-CDK-
inhibitor complexes.  Mol Cell Biol 1999, 19(3):1981-1989.
43. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K,
Herlyn M, Enders GH: Induction of p21(WAF1/CIP1) and inhi-
bition of Cdk2 mediated by the tumor suppressor
p16(INK4a).  Mol Cell Biol 1999, 19(5):3916-3928.
44. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading
frames of the INK4a tumor suppressor gene encode two
unrelated proteins capable of inducing cell cycle arrest.  Cell
1995, 83(6):993-1000.
45. Sherr CJ: Divorcing ARF and p53: an unsettled case.  Nat Rev
Cancer 2006, 6(9):663-673.
46. Tsuyama N, Miura M, Kitahira M, Ishibashi S, Ide T: SV40 T-antigen
is required for maintenance of immortal growth in SV40-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cell Division 2007, 2:10 http://www.celldiv.com/content/2/1/10
Page 5 of 5
(page number not for citation purposes)
transformed human fibroblasts.  Cell Struct Funct 1991,
16(1):55-62.
47. Tahara H, Sato E, Noda A, Ide T: Increase in expression level of
p21sdi1/cip1/waf1 with increasing division age in both nor-
mal and SV40-transformed human fibroblasts.  Oncogene 1995,
10(5):835-840.
48. Finkel T: Oxidant signals and oxidative stress.  Curr Opin Cell Biol
2003, 15(2):247-254.
49. Konishi H, Tanaka M, Takemura Y, Matsuzaki H, Ono Y, Kikkawa U,
Nishizuka Y: Activation of protein kinase C by tyrosine phos-
phorylation in response to H2O2.  Proc Natl Acad Sci USA 1997,
94(21):11233-11237.
50. Wheaton K, Riabowol K: Protein kinase C delta blocks immedi-
ate-early gene expression in senescent cells by inactivating
serum response factor.  Mol Cell Biol 2004, 24(16):7298-7311.
51. Iida S, Hirota T, Morisaki T, Marumoto T, Hara T, Kuninaka S, Honda
S, Kosai K, Kawasuji M, Pallas DC, Saya H: Tumor suppressor
WARTS ensures genomic integrity by regulating both
mitotic progression and G1 tetraploidy checkpoint function.
Oncogene 2004, 23(31):5266-5274.
52. Yang X, Yu K, Hao Y, Li DM, Stewart R, Insogna KL, Xu T: LATS1
tumour suppressor affects cytokinesis by inhibiting LIMK1.
Nat Cell Biol 2004, 6(7):609-617.
53. Bothos J, Tuttle RL, Ottey M, Luca FC, Halazonetis TD: Human
LATS1 is a mitotic exit network kinase.  Cancer Res 2005,
65(15):6568-6575.
54. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector
DL, Hannon GJ, Lowe SW: Rb-mediated heterochromatin for-
mation and silencing of E2F target genes during cellular
senescence.  Cell 2003, 113(6):703-716.
55. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM,
Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, Pehrson
JR, Berger JM, Kaufman PD, Adams PD: Formation of MacroH2A-
containing senescence-associated heterochromatin foci and
senescence driven by ASF1a and HIRA.  Dev Cell 2005,
8(1):19-30.
56. Narita M, Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA,
Myers MP, Lowe SW: A novel role for high-mobility group a
proteins in cellular senescence and heterochromatin forma-
tion.  Cell 2006, 126(3):503-514.
57. Funayama R, Saito M, Tanobe H, Ishikawa F: Loss of linker histone
H1 in cellular senescence.  J Cell Biol 2006, 175(6):869-880.
58. Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R,
Poole JC, Roninson IB: p21Waf1/Cip1/Sdi1-induced growth
arrest is associated with depletion of mitosis-control pro-
teins and leads to abnormal mitosis and endoreduplication in
recovering cells.  Oncogene 2000, 19(17):2165-2170.
59. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW,
McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M,
Cichowski K: A negative feedback signaling network underlies
oncogene-induced senescence.  Cancer Cell 2006, 10(6):459-472.
60. Shay JW, Roninson IB: Hallmarks of senescence in carcinogen-
esis and cancer therapy.  Oncogene 2004, 23(16):2919-2933.
61. Dimri GP: What has senescence got to do with cancer?  Cancer
Cell 2005, 7(6):505-512.
62. Schmitt CA: Cellular senescence and cancer treatment.  Bio-
chim Biophys Acta 2007, 1775(1):5-20.